All Mylan articles
-
BusinessPfizer’s Upjohn to merge with Mylan
Deal combines Pfizer’s off-patent drug portfolio with Mylan’s generics
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessFDA warns Pfizer subsidiary over Epipen malfunctions
Manufacturer did not fully investigate reports of patients dying after auto-injector failures
-
BusinessMylan settles Epipen overcharging allegations
Company will pay US Department of Justice $465m for avoiding paying rebates to government healthcare systems
-
BusinessIndia probes Roche over biosimilars
Mylan and Biocon claim Roche abused its market dominance to quash generic breast cancer antibodies
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessMylan may lay off up to 3500 staff
The move forms part of the US generic firm’s restructuring efforts
-
BusinessMylan expands in dermatology
$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio
-
BusinessMylan to buy Meda in further generics consolidation
£6.9bn deal will give combined company ‘critical mass’ in US market
-
Business
Perrigo nabs US rights to AZ Crohn’s drug
Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
BusinessGenerics give injectables a shot
A rash of recent acquisitions sees generics companies eager to enter speciality manufacturing market
-
Business
Generic Actos approved
Mylan, Ranbaxy and Teva have won US marketing approval for their generic versions of Actos diabetes tablets
-
Business
Pfizer secures Sandwich buyer
The R&D site in Sandwich, UK, has been bought by a private consortium